Horizon Pharma plc / Crealta Holdings LLC

Chronic Refractory Gout

Disease Overview

Chronic refractory gout is a severe form of gout in which uric acid stays elevated and inflammatory flares persist despite maximum-dose oral urate-lowering therapy. It affects roughly 50,000 Americans, primarily older men with comorbidities (CKD, transplant, allopurinol intolerance), and produces tophi, joint destruction, and disabling chronic arthritis when uncontrolled.

Competitive Landscape

First-line urate-lowering therapy is dominated by inexpensive oral xanthine oxidase inhibitors—allopurinol (generic) and Takeda's febuxostat (Uloric)—plus the uricosuric probenecid and adjunctive anti-inflammatories colchicine and Ironwood/AstraZeneca's lesinurad (Zurampic, since discontinued). Krystexxa (pegloticase) sits at the end of that ladder as the only FDA-approved biologic for chronic refractory gout, indicated when oral ULTs fail or are contraindicated. Its commercial ceiling has been limited by IV infusion logistics, anti-drug antibodies driving infusion reactions and loss of response, and a treated base of just 4,000-5,000 patients out of the ~50,000 US refractory population since 2010 approval. Horizon's thesis was that Crealta had under-promoted Krystexxa and that a 41-person rheumatology sales force, orphan-disease commercial muscle, and patent protection through 2027 could re-rate the asset—projecting $70-80M of net sales in year one. The deal repositions Krystexxa from a niche infusion biologic into Horizon's orphan/rare-disease engine and sets up the later methotrexate co-administration strategy that materially expanded durable response rates.